Venetoclax in Chronic Lymphocytic Leukemia Effectiveness and Real-life Treatment Management - VERONE
Phase of Trial: Phase IV
Latest Information Update: 05 Dec 2018
At a glance
- Drugs Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms VERONE
- Sponsors AbbVie
- 28 Nov 2018 Planned number of patients changed from 250 to 270.
- 21 Mar 2018 Status changed from not yet recruiting to recruiting.
- 01 Feb 2018 New trial record